Phased implementation of pathogen-reduced platelets in a health system facilitates increased manufacturing at the blood center.

ABSTRACT:

Background

Pathogen reduction treatment (PRT) reduces the risk of transfusion-transmitted infections from established and emerging organisms. Manufacturing, however, is complex. In our university health system, we phased in pathogen-reduced platelets (PR PLTs) by patient population. We then assessed the implementation strategy and investigated factors in the supply chain that prevented us from meeting the goal of providing greater than 90% PR PLTs within 6 months.

Study design and methods

In Phase 1, PR PLTs were provided in the outpatient cancer center. Phase 2 added inpatients undergoing bone marrow transplantation, and Phase 3 included all patients. In Phase 4, the blood center implemented manufacturing optimization strategies. Product supply and usage during the first 23

SUBMITTER: Allen ES 

PROVIDER: S-EPMC6852374 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature